ARTICLE

The copy number variant involving part of the α7 nicotinic receptor gene contains a polymorphic inversion

Rachel H Flomen[1], Angela F Davies[2], Marta Di Forti[1], Caterina La Cascia[1], Caroline Mackie-Ogilvie[2], Robin Murray[1] and Andrew J Makoff*,[1]

[1]Department of Psychological Medicine, Division of Psychological Medicine, Institute of Psychiatry, King's College London, London, UK; [2]Cytogenetics Department, Guy's Hospital, London, UK

The α7 nicotinic acetylcholine receptor gene (*CHRNA7*) is located at 15q13–q14 in a region that is strongly linked to the P50 sensory gating deficit, an endophenotype of schizophrenia and bipolar disorder. Part of the gene is a copy number variant, due to a duplication of exons 5–10 and 3′ sequence in *CHRFAM7A*, which is present in many but not all humans. Maps of this region show that the two genes are in opposite orientation in the individual mainly represented in the public access human DNA sequence database (Build 36), suggesting that an inversion had occurred since the duplication. We have used fluorescent *in situ* hybridization to investigate this putative inversion. Analysis of interphase chromosomes in 12 individuals confirms the occurrence of an inversion and indicates that *CHRFAM7A* exists in both orientations with similar frequency. We showed that the 2 bp deletion polymorphism in exon 6 of *CHRFAM7A* is in strong linkage disequilibrium with the inversion polymorphism ($r^2 = 0.82$, CI 0.53–1.00, $P = 0.00003$), which can therefore be used as a surrogate marker. Previous associations of endophenotypes of schizophrenia with the 2 bp deletion might therefore be due to the orientation of the duplicon containing *CHRFAM7A*.
European Journal of Human Genetics (2008) **16**, 1364–1371; doi:10.1038/ejhg.2008.112; published online 11 June 2008

Introduction

The α7 nicotinic acetylcholine receptor gene (*CHRNA7*) is located at 15q13–q14, a region strongly linked to the P50 sensory gating deficit, an endophenotype of schizophrenia[1,2] and bipolar disorder.[3,4] The peak LOD score (5.3) occurs at a marker in *CHRNA7*, with linkage also supported by pharmacological evidence.[5] Attempts to demonstrate linkage of this region to either schizophrenia or bipolar disorder have had mixed results, with one study showing linkage to bipolar disorder[6] and several studies showing only weak evidence for linkage to schizophrenia.[1,2,7,8] There is also evidence for association of *CHRNA7* with schizophrenia and bipolar disorder.[9] Together, these results suggest that P50 may be modulated by variant(s) in the *CHRNA7* region as one of many genetic defects that increases susceptibility to the major psychoses. This region has also been linked to two idiopathic epilepsies.[10,11]

Genetic analysis of 15q13–q14 is complicated by a large duplication of part of *CHRNA7*.[12] We have previously examined the sequence relationships of this and other duplications in this region and showed that the partial duplication of *CHRNA7* (*CHRFAM7A*) is a hybrid of

*Correspondence: Dr AJ Makoff, Department of Psychological Medicine, Division of Psychological Medicine, Institute of Psychiatry, King's College London, de Crespigny Park, Denmark Hill, London SE 8AF, UK.
Tel: +44 0 207 848 0638; Fax: +44 0 207 848 0051;
E-mail: a.makoff@iop.kcl.ac.uk

CHRNA7 and an unrelated sequence *FAM7A*, of which there are several copies.[13] Both *FAM7A* and *CHRFAM7A* are transcribed, but translation is uncertain.

Our map of 15q13–q14[13] (Figure 1, bottom) showed that *CHRNA7* and *CHRFAM7A* are in opposite orientations in the DNA sequence database (Build 36), which is mostly represented by the RP11 library. This suggests that an inversion of *CHRFAM7A* may have taken place after the partial duplication that generated it.[13] Later assemblies of the human sequence (NT_010194), after earlier incorrect assemblies, support this map. There is now a continuous tiling path of clones between the two ends of the map, confirming our finding that *CHRNA7* and *CHRFAM7A* are in opposite orientation in the RP11 individual.[14]

The partial duplication of *CHRNA7* is a recent event unique to humans, with only *CHRNA7* and not *CHRFAM7A* in other higher primates.[15] Chromosomes both with and without *CHRFAM7A* have been identified in several human populations, indicating a copy number variant (CNV) with respect to the duplicated part common to *CHRNA7* and *CHRFAM7A*. We have recently shown association between this CNV and the major psychoses.[16] This study found that the homozygous *CHRFAM7A* null genotype was rare, but the heterozygote occurred in 24% of psychosis patients compared to 16% of controls ($P = 0.04$). We have deduced the likely structure of chromosomes with this null *CHRFAM7A* allele,[14] which may represent a persisting ancestral chromosome. Other more recent ancestral


Figure 1 Model for generation of the duplicon containing *CHRFAM7A*. Homologous segments are indicated by the same letters, with positions and orientation of genes *CHRNA7*, *CHRFAM7A* and *FAM7A* shown below. In the model, two minor variants of the ancestral structure Ia (structures Ib and Ic) undergo a duplication mediated by non-allelic homologous recombination (NAHR) at the direct repeats QRAZRM to generate an intermediate structure, which undergoes non-homologous deletion to bring segment A adjacent to segment H in structure IIa. (See Supplementary Figure 2 for alternative scheme in which structure IIa is generated from structures Ib and Ic in one step.) Inversion of segments HSRZ (in the *CHRFAM7A* duplicon) needs to occur to produce the RP11 structure (structure IIb), with deletion of the most telomeric segments AZ occurring here or at an earlier step, both occurring by NAHR. Approximate sizes and positions of the three fluorescent probes are shown above appropriate segments for structures IIa and IIb (yellow, RP11-143J24; green, 13H18; red, 30H17). Positions of duplicons associated with *CHRNA7* and *CHRFAM7A* and the breakpoints 4 and 5 (BP4 and 5), involved in inv dup (15) supernumerary marker chromosomes are shown below structure IIb.

chromosomal structures predating the putative inversion may also exist. In this paper, we demonstrate examples of both pre- and post-inversion forms showing that such an ancestral chromosome does persist and is very common.

Materials and methods

Identification of chimpanzee clones

Orthologous *Pan troglodytes* clones were identified using BLASTN against fully sequenced clones (nr/nt) or against genome survey sequences (gss) for clone end sequences, and aligned with human contig NT_010194.16 using Blast Two Sequences (www.ncbi.nlm.nih.gov/blast/Blast.cgi).

Sample

A total of 12 lithium heparin-treated fresh blood samples were from the First Onset of Psychosis Study (Institute of Psychiatry). Clinical data are summarized in Table 1.

DNA preparation and assays

DNA was prepared from 1 ml of blood using the QIAamp DNA blood midi kit (Qiagen). The 2 bp deletion genotype and copy number of *CHRFAM7A* were determined as described previously.[16]

Probe selection for fluorescence *in situ* hybridization

BAC clone (RP11-143J24, AC087455; http://bacpac.chori.org/) was selected as fluorescence *in situ* hybridization (FISH) probe for segment B. For duplicated segments S and H (Figure 1), cosmid clones were used as probes because their smaller size (approximately 40 kb) enabled more precise targeting. PCR primers GACCTAGATCCACAGTA AG, CAGGTGGAGATTCCAAGAGC (segment S, from RP13-395E19, AC139426), TATCTATCAGCCCATCTGAG, CACG

CACGATGAGCACCTCC (segment H, from RP11-382B18, AC019322) were used to amplify genomic DNA for cosmid library screening. PCR products were random primer labeled with α^{32}P dCTP (specific activity, $1-2 \times 10^6$ c.p.m. per ml hybridization mixture) using the RediprimeII kit (Amersham Biosciences). LA15NC01, a chromosome 15 cosmid library (www.hgmp.mrc.ac.uk/geneservice) was screened using Express-hyb buffer (Amersham Biosciences). Individual positive clones 30H17 (segment H) and 13H18 (segment S) were confirmed by PCR using the original and additional flanking PCRs (see Figure 1 for locations of all three probes).

Chromosome studies

Molecular cytogenetic studies were performed on chromosomes taken from peripheral blood cells. Chromosome preparations were obtained according to standard protocols.[17] FISH was performed as previously described.[18] Cosmid clones were labeled with biotin or digoxygenin by nick translation (Invitrogen). Biotin was detected with an avidin-fluorescein isothiocyanate system (green) and digoxygenin was detected with anti-digoxygenin-rhodamine (red). The yellow signal was obtained by independently labeling the BAC clone with biotin and digoxygenin, which when colocalized give yellow. Slides were mounted in Vectashield (Vector Laboratories) containing 4,6-diamidino-2-phenylindole as counterstain. Hybridization signals were visualized and analyzed using an Isis FISH Imaging System (Metasystems).

Linkage disequilibrium estimates

We calculated r^2 estimates of linkage disequilibrium (LD) between the inversion polymorphism and the 2 bp

Table 1 FISH analysis of *CHRFAM7A* duplicon

Sample	Ethnicity[a]	Diagnosis[b]	No. of interphases			CN[a]	Inv genotype[b]	2 bp genotype[c]
			Total	Allele 2	Allele 3			
109	WC	BPD	90	0	21	2	33	33
110	WC/AC	BPD	93	0	19	2	33	33
111	WC	SZ	50	0	24	1	13	13
117	WC	SZ	150	22	8	2	23	23
161	WC	P	132	25	6	2	23	23
179	WC	SZ	62	15	0	1	12	12
200	A	SZ	140	14	0	2	22	22
201	ASA	P	76	0	10	1	13	13
205	WC	C	121	19	2	2	23	23
211	A	P	52	9	10	2	23	23
240	WC	P	143	15	20	2	**23**	**33**
311	WC	C	71	8	8	2	23	23

Abbreviations: A, African; ASA, Afro-South American; BPD, bipolar disorder; C, control; P, psychosis; SZ, schizophrenia; WC, white Caucasian; WC/AC, mixed race (AC, Afro-Carribbean).
[a]*CHRFAM7A* copy number.
[b]Inversion genotype: 1, *CHRFAM7A* null allele; 2, *CHRFAM7A* inverted relative to CHRNA7 (as in the database); 3, *CHRFAM7A* direct orientation.
[c]2 bp deletion genotype: 1, *CHRFAM7A* null; 2, *CHRFAM7A* wt; 3, *CHRFAM7A* 2bpdel. The genotypes of sample 240 that prevent perfect LD between the polymorphisms are shown in bold.

deletion polymorphism using Gene Counting[19] and 2LD.[20] Because of the occasional presence of the *CHRFAM7A* null allele, a few samples were haploid for either polymorphism. To overcome this complication, haplotype frequencies for the two polymorphisms were initially estimated for the diploid samples using Gene Counting. These frequency estimates were then adjusted to include the haplotypes for the haploid samples, where the phase is always unambiguous. We obtained r^2 and standard error estimates from the adjusted estimated haplotype frequencies using 2LD.

Results
A model for partial duplication of *CHRNA7*
A map showing the duplication structure of 15q13–q14 for the RP11 individual is shown as structure IIb (Figure 1, bottom), with *CHRNA7* and *CHRFAM7A* in opposite orientations. This is a modified version of a map shown previously.[14] Segments that share > 5 kb with > 95% sequence identity (mostly > 99% identity) are shown in color, with homologous segments sharing the same letter. Duplicons associated with the duplication of *CHRNA7* run from segments HS (in blue) to segments RZARQ (in yellow), where the sequences diverge in segment Q.

To derive a model for the creation of *CHRFAM7A*, we considered its likely ancestral structure. The *CHRFAM7A* null allele is probably part of a chromosome structure that predates the creation of *CHRFAM7A* and may represent a close approximation to this ancestral structure. Structure Ia (Figure 1, top) represents our best estimate of the ancestral human structure for this region, combining our data on RP11, the *CHRFAM7A* null allele and chimpanzee sequence (Supplementary Figure 1). Figure 1 shows a plausible series of steps whereby the RP11 structure (IIb) might have arisen from the presumed ancestral structure (Ia). Two key events in the creation of CHRFAM7A are a 2.1 Mb duplication followed by a 1.6 Mb deletion, via an intermediate structure containing two complete copies of *CHRNA7*. It is possible, however, that these two steps might have occurred as a single meiotic event (Supplementary Figure 2). Whether or not these two steps were combined, our proposed scheme predicts the existence of structure IIa. To generate the RP11 structure (IIb) from structure IIa requires inversion of segments HSRZ, probably by non-allelic homologous recombination (NAHR) between the two inverted repeats that flank segments H and S (defining a 320 kb region). (As presented in Figure 1, 60 kb deletion of segments AZ is also required, although this might have occurred at an earlier step.) An important question, therefore, is whether there is any evidence for structure IIa as well as the known structure IIb, thereby identifying a structural polymorphism with *CHRFAM7A* in either orientation. Because the putative inversion of segments HSRZ contains only duplicated segments with no junction unique to either orientation (Figure 1), it is not possible to investigate its orientation by examination of small regions, such as by PCR.

Fluorescent labeling and FISH
To determine the orientation of the *CHRFAM7A* duplicon, three fluorescent probes, located in segments B, S and H (shown on structures IIa and IIb in Figure 1), were used. FISH results were visualized as a string of fluorescent signals at interphase, with two alternative patterns of the three probes adjacent to the *CHRFAM7A* duplicon and red and green signals only for the distal *CHRNA7* duplicon (Figure 2). Because of the large distance between the two duplicons (approximately 1.8 Mb) it was only occasionally possible to observe all five signals together in the same string (Figure 2a and b). Where two copies of *CHRFAM7A* were present, some nuclei showed two strings of signals, but it was rarely possible to observe more than one informative string per nucleus in the same focal plane, such as in Figure 2a. This result clearly demonstrates that the orientation of *CHRFAM7A* is polymorphic. A few experiments were also performed with an alternative labeling pattern to control for possible labeling artifacts, but the resulting order of segments was identical (not shown).

A total of 12 samples were analyzed by careful examination of a minimum of 50 individual interphases per sample (Table 1). We determined the orientation of the *CHRFAM7A* inversion according to the order of the three signals, assigning allele 2 to yellow-green-red and allele 3 to yellow-red-green. We also determined copy number of *CHRFAM7A* for each sample, enabling us to identify all three alleles: allele 1 (*CHRNA7* null) or alleles 2 or 3 (the two alternative orientations of *CHRFAM7A*). Alleles 2 and 3 appear to be of similar frequency and all three alleles were observed in both white Caucasian and black subjects.

Designation of each orientation was initially performed blind to *CHRFAM7A* copy number. For the nine samples with a copy number of 2, we analyzed further interphases to minimize error, but for sample 200, their quality did not allow us to interpret more than 14 interphases. For samples 117, 161 and 205 that are apparently heterozygous for orientation but display a disparity in the two orientations, we re-examined interphases with the infrequent orientation to confirm their validity.

The 2 bp deletion polymorphism is a surrogate marker for the inversion polymorphism
It is possible that due to lack of recombination within the inversion, genetic isolation of this DNA may have occurred. To investigate this, all 12 samples were genotyped for a polymorphism specific to *CHRFAM7A*, the 2 bp deletion polymorphism within exon 6. We genotyped this polymorphism by a combination of two assays as described previously[16] to identify all three alleles: allele 1 (*CHRFAM7A* null, as above), allele 2 (wt *CHRFAM7A*), allele 3

Figure 2 Examples of informative interphase chromosomes. (**a**) A rare example of two informative alleles in the same nucleus: allele 2 (yellow-green-red, *CHRFAM7A* inverted with respect to *CHRNA7* as in RP11 structure) and allele 3 (yellow-red-green (red-green), *CHRFAM7A* in same orientation as *CHRNA7*), (**b**) a rare unambiguous example of all five signals on same string: allele 2 (yellow-green-red-red-green), (**c**) allele 2, (**d**–**f**) allele 3. See Figure 1 for location of probes.

(*CHRFAM7A* with 2 bp deletion). Comparison of the two polymorphisms in chromosomes containing *CHRFAM7A* (Table 1) revealed strong LD between them ($r^2 = 0.82$, CI 0.53–1.00, $P = 0.00003$), with the 2 bp deletion almost always occurring when *CHRFAM7A* is in the same orientation as *CHRNA7*. Only sample 240 prevents perfect LD between the two polymorphisms. In the RP11 individual, where *CHRFAM7A* is in the opposite orientation to *CHRNA7*,[14] the 2 bp deletion is absent in both relevant BAC clones (RP11-382B18, AC019322; RP11-40J8, AC010799), which is consistent with this result.

Discussion

We have shown here that the CNV at 15q13–q14, which includes part of *CHRNA7*, contains a duplicon that frequently exists in either orientation and therefore contains a very common polymorphic inversion. We have previously reported that this CNV has a null allele frequency of around 10%.[16] Thus, the remaining 90% of chromosomes containing *CHRFAM7A* are approximately equally divided between the two alternative orientations.

The proximal end of chromosome 15 contains many segmental duplications, which are probably responsible for some of the genomic rearrangements known to occur in this region.[21,22] In a recent paper we presented a comprehensive study of the arrangement of segmental duplications in the individual whose DNA was used to construct the RP11 library and responsible for the bulk of sequence information on the public access human sequence databases.[14] In Figure 1 and the supplementary figures we propose a plausible way by which the only fully known structure for this region might have been generated. We already had evidence for the existence of a chromosome structure without the *CHRFAM7A* duplicon and adjacent duplicon, which could be represented by structures Ia, Ib and/or Ic in our proposed scheme. We now have evidence for a structure with the *CHRFAM7A* duplicon in opposite orientation to that found in the RP11 individual, which is consistent with structure IIa. These observations therefore support the existence of a pathway for the evolution of 15q13–q14, similar to that proposed, and for the persistence of some of the proposed ancestral structures in present human populations.

We have found that the *CHRFAM7A* inversion polymorphism is in strong LD with the 2 bp deletion polymorphism within exon 6 of *CHRFAM7A*. A similar situation has arisen with the well-studied 900 kb polymorphic inversion at 17q21.31, each orientation of which is

strongly associated with one of two haplotypes H1 and H2 that appear to have diverged around 3 Myr ago.[23] Other studies have described similarly strong patterns of LD between CNVs and SNPs, where the CNV is ancestral as evident from the same strong LD in different ethnicities.[24–26] Strong LD has also been observed between other structural variants and SNPs.[27] These strong LD relationships have suggested that these genomic variants have arisen as single ancestral events on a particular haplotype background rather than from repeated mutational events. Where it occurs with inversions, such strong LD is likely to persist for a very long time, due to lack of recombination within the inversion. The 2 bp deletion is therefore likely to be part of a haplotype associated with the *CHRFAM7A* inversion and supports the notion of an ancestral relationship between the two alternative orientations.

Both the 2 bp deletion and the orientation of *CHRFAM7A* may have functional consequences. The most likely effect of the 2 bp deletion would be to disrupt the reading frame to prevent translation of full-length *CHRFAM7A* protein. However, it is unknown whether *CHRFAM7A* is translated. Alternatively, *CHRFAM7A* mRNA may affect *CHRNA7* expression by competition for transcription factors. If so, the inversion could affect expression of *CHRFAM7A* mRNA, modulating *CHRNA7* expression. One of the presumed breakpoints of the inversion (indicated above structure IIa, Figure 1) lies around 25 kb upstream of *CHRFAM7A*, possibly altering the location or effect of regulatory elements. However, for *CHRFAM7A* gene products to influence expression of *CHRNA7*, both genes must be expressed in the same cell, but, with different promoter and 5′ regions, this is far from certain.

There may be biological consequences of the orientation of *CHRFAM7A* that are independent of expression. Some inversions are known to affect the risk of genomic rearrangements in meiosis and therefore affect the next generation. One example is an inversion at 15q11–q13 that is strongly overrepresented in mothers of Angelman syndrome (AS) patients[28] and which we recently reanalyzed in light of our improved map of this region of chromosome 15.[14] This and other examples at 4p16, 5q35, 7q11.23, 8p23 and Yp11.2 have been recently reviewed.[29]

When *CHRFAM7A* and *CHRNA7* are in opposite orientation, there is likely to be a small increased risk of inv dup (15) syndrome.[30] This syndrome occurs in around 1 in 10 000 live births, with phenotypes including autism and seizures, and arises from a maternal duplication on a supernumerary marker chromosome that includes the critical imprinted region deleted in Prader–Willi and Angelman syndromes (PWS/AS). More than half of cases involve NAHR between inverted repeats in 15q13–q14 (breakpoints BP4 and 5, under structure IIb in Figure 1),[31] which in the RP11 structure can partly be accounted for by the inverted relationship between the *CHRNA7* and

CHRFAM7A duplicons.[14] If NAHR occurred between these repeats within the same chromatid, an inversion of the region between BP4 and 5 would occur. Interestingly, a common polymorphic inversion in 15q13.3 has been recently reported.[32] Although its exact location was not determined, it is clear from the location of the probes used that it is not the same as the smaller *CHRFAM7A* inversion within BP4 described here and is consistent with inversion of the region between BP4 and 5. It will be interesting to know the limits of this inversion and its LD relationship with the *CHRFAM7A* inversion.

When *CHRFAM7A* and *CHRNA7* are in the same orientation, there is likely to be a small increased risk of deletions or duplications of *CHRNA7* and flanking regions. Individuals with *CHRNA7* deletions are likely to be viable as *CHRNA7* null mice are without a major phenotype[33] and, in humans, a small proportion of PWS/AS patients have large deletions that extend to *CHRNA7*.[34] Individuals with *CHRNA7* duplications would also be expected to be viable as patients with inv dup (15) syndrome often have three copies of *CHRNA7* as do largely asymptomatic subjects with the equivalent paternal duplications.[31] Our 2 bp deletion data suggest infrequent *CHRNA7* deletions (<0.6%), as our assay would have detected such a deletion in patients homozygous for the 2 bp deletion in *CHRFAM7A*.[16] Other copy number studies have indicated a higher frequency of deletions/duplications of *CHRNA7* (11[35] and 20%,[36] mainly due to deletions), but most of these appear to be much smaller deletions/duplications than BP4–5. However, in a recent study of about 2000 mental retardation cases, nine individuals (six unrelated) were identified with BP4–5 deletions and had phenotypes that also included seizures, abnormal EEG and/or dysmorphic features.[32] When around 1000 controls were investigated in the same study, one BP4–5 duplication was detected but no similar deletions. It was suggested that these rare deletions and duplications of BP4–5 might be linked to the large BP4–5 inversion. Whether such a link is established, our data strongly suggest a link with the smaller *CHRFAM7A* inversion involving NAHR between *CHRNA7* and *CHRFAM7A* duplicons when in direct orientation.

Because of the strong LD between them, the 2 bp deletion polymorphism can be used as a surrogate for the *CHRFAM7A* inversion polymorphism. We can therefore reassess previous studies involving the 2 bp deletion polymorphism. A French study reported an association between the 2 bp deletion and abnormal P50.[37] A more recent study reported association between the 2 bp deletion and poor episodic memory, another endophenotype of schizophrenia.[38] It is therefore possible that the *CHRFAM7A* inversion is associated with some endophenotypes of schizophrenia. In our earlier study, we found no association of the 2 bp deletion with schizophrenia, bipolar disorder or psychosis, although we did find an association

between heterozygotes for the *CHRFAM7A* null allele and psychosis.[16] The same French group described above also failed to find association of the 2 bp deletion with schizophrenia.[37] A Chinese group investigating the 2 bp deletion polymorphism without considering the *CHRFAM7A* CNV reported no association with schizophrenia[39] but found association of the 2 bp deletion with bipolar disorder.[40] These differences may be due to greater statistical power required to detect association with genetically more complex phenotypes compared to endophenotypes. Such a pattern was seen with the *CHRNA7* region of 15q13–q14, which showed strong linkage to the P50 endophenotype but only weak linkage to schizophrenia within the same study.[1]

We have shown that, where present, *CHRFAM7A* exists in either orientation. It therefore appears that at least two versions of this region of 15q13–q14 ancestral to the version presented in the database have persisted at a significant frequency. It remains to be determined whether any of these common genomic variants is involved in psychosis. Such important genetic studies have been made feasible by our observation that the *CHRFAM7A* inversion polymorphism is in strong LD with the 2 bp deletion polymorphism in exon 6 of *CHRFAM7A* as the latter, which is more practical than FISH for large-scale genotyping, can therefore be used as a surrogate marker. We plan to investigate association of these variants with P50 and other endophenotypes of schizophrenia in a large sample of psychosis patients and their unaffected relatives.

References
1 Freedman R, Coon H, Myles-Worsley M *et al*: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. *Proc Natl Acad Sci USA* 1997; **94**: 587–592.
2 Leonard S, Gault J, Moore T *et al*: Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. *Am J Med Genet* 1998; **81**: 308–312.
3 Olincy A, Martin L: Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. *Am J Psychiatry* 2005; **162**: 43–49.
4 Schulze KK, Hall MH, McDonald C *et al*: P50 auditory evoked potential suppression in bipolar disorder patients with psychotic features and their unaffected relatives. *Biol Psychiatry* 2007; **62**: 121–128.
5 Weiland S, Bertrand D, Leonard S: Neuronal nicotinic acetylcholine receptors: from the gene to the disease. *Behav Brain Res* 2000; **113**: 43–56.
6 Turecki G, Grof P, Grof E *et al*: Mapping susceptibility genes for bipolar disorder: a pharmacogenetic approach based on excellent response to lithium. *Mol Psychiatry* 2001; **6**: 570–578.
7 Kaufmann CA, Suarez B, Malaspina D *et al*: NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. *Am J Med Genet* 1998; **81**: 282–289.
8 Riley BP, Makoff A, Mogudi-Carter M *et al*: Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. *Am J Med Genet* 2000; **96**: 196–201.
9 Stassen HH, Bridler R, Hagele S *et al*: Schizophrenia and smoking: evidence for a common neurobiological basis? *Am J Med Genet* 2000; **96**: 173–177.
10 Elmslie FV, Rees M, Williamson MP *et al*: Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. *Hum Mol Genet* 1997; **6**: 1329–1334.
11 Neubauer BA, Fiedler B, Himmelein B *et al*: Centrotemporal spikes in families with rolandic epilepsy: linkage to chromosome 15q14. *Neurology* 1998; **51**: 1608–1612.
12 Gault J, Robinson M, Berger R *et al*: Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (*CHRNA7*). *Genomics* 1998; **52**: 173–185.
13 Riley BP, Williamson M, Collier DA, Wilkie H, Makoff AJ: A 3Mb map of a large segmental duplication overlapping a7 nicotinic acetylcholine receptor gene (*CHRNA7*) at human 15q13–q14. *Genomics* 2002; **79**: 197–209.
14 Makoff A, Flomen RH: Detailed analysis of 15q11–q14 sequence fully reveals large segmental duplications at breakpoints for Prader–Willi and Angelman syndromes and other 15q genomic disorders. *Genome Biol* 2007; **8**: R114.1–R114.16.
15 Locke DP, Archidiacono N, Misceo D *et al*: Refinement of a chimpanzee pericentric inversion breakpoint to a segmental duplication cluster. *Genome Biol* 2003; **4**: R50.1–R50.9.
16 Flomen RH, Breen G, Collier D, St Clair D, Makoff AJ: Association study of CHRFAM7A copy number and 2 bp deletion polymorphisms with schizophrenia and bipolar affective disorder. *Am J Med Genet B Neuropsychiatr Genet* 2006; **141**: 571–575.
17 Clouston HJ: Lymphocyte culture; in Rooney ED (ed): Human Cytogenetics, a practical approach, Oxford University Press, 2001; **1**: Constitutional analysis Chapter 3, pp33–53.
18 Davies AF, Mirza G, Sekhon G *et al*: Delineation of two distinct 6p deletion syndromes. *Hum Genet* 1999; **104**: 64–72.
19 Curtis D, Knight J, Sham PC: Program report: GENECOUNTING support programs. *Ann Hum Genet* 2006; **70**: 277–279.
20 Zhao JH: 2LD, GENECOUNTING and HAP: computer programs for linkage disequilibrium analysis. *Bioinformatics* 2004; **20**: 1325–1326.
21 Eichler EE: Recent duplication domain accretion and the dynamic mutation of the human genome. *Trends Genet* 2001; **17**: 661–669.
22 Zody MC, Garber M, Sharpe T *et al*: Analysis of the DNA sequence and duplication history of human chromosome 15. *Nature* 2006; **440**: 671–675.
23 Stefansson H, Helgason A, Thorleifsson G *et al*: A common inversion under selection in Europeans. *Nat Genet* 2005; **37**: 129–137.
24 Locke DP, Sharp AJ, McCarroll SA *et al*: Linkage disequilibrium and heritability of copy-number polymorphisms within duplicated regions of the human genome. *Am J Hum Genet* 2006; **79**: 275–290.
25 McCarroll SA, Hadnott TN, Perry GH *et al*: Common deletion polymorphisms in the human genome. *Nat Genet* 2006; **38**: 86–92.
26 Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA: Common deletions and SNPs are in linkage disequilibrium in the human genome. *Nat Genet* 2006; **38**: 82–85.
27 Newman TL, Rieder MJ, Morrison VA *et al*: High-throughput genotyping of intermediate-size structural variation. *Hum Mol Genet* 2006; **15**: 1159–1167.
28 Gimelli G, Pujana MA, Patricelli MG *et al*: Genomic inversions of human chromosome 15q11–q13 in mothers of Angelman

syndrome patients with class II (BP2/3) deletions. *Hum Mol Genet* 2003; **12**: 849–858.

29 Sharp AJ, Cheng Z, Eichler EE: Structural variation of the human genome. *Annu Rev Hum Genet* 2006; **7**: 407–442.

30 Battaglia A: The inv dup(15) or idic(15) syndrome: a clinically recognisable neurogenetic disorder. *Brain Dev* 2005; **27**: 365–369.

31 Wang NJ, Liu D, Parokonny AS, Schanen NC: High-resolution molecular characterization of 15q11–q13 rearrangements by array comparative genomic hybridization (array CGH) with detection of gene dosage. *Am J Hum Genet* 2004; **75**: 267–281.

32 Sharp AJ, Mefford HC, Li K *et al*: A recurrent 15q13.3 micro-deletion syndrome associated with mental retardation and seizures. *Nat Genet* 2008; **40**: 322–328.

33 Orr-Urtreger A, Goldner FM, Saeki M *et al*: Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. *J Neurosci* 1997; **17**: 9165–9171.

34 Sahoo T, Bacino CA, German JR *et al*: Identification of novel deletions of 15q11q13 in Angelman syndrome by array-CGH: molecular characterization and genotype–phenotype correlations. *Eur J Hum Genet* 2007; **15**: 943–949.

35 Sharp AJ, Hansen S, Selzer RR *et al*: Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. *Nat Genet* 2006; **38**: 1038–1042.

36 Redon R, Ishikawa S, Fitch KR *et al*: Global variation in copy number in the human genome. *Nature* 2006; **444**: 444–454.

37 Raux G, Bonnet-Brilhault F, Louchart S *et al*: The −2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. *Mol Psychiatry* 2002; **7**: 1006–1011.

38 Dempster EL, Toulopoulou T, McDonald C *et al*: Episodic memory performance predicted by the 2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene. *Am J Psychiatry* 2006; **163**: 1832–1834.

39 Lai IC, Hong CJ, Tsai SJ: Association study of a nicotinic receptor variant with schizophrenic disorders. *Neuropsychobiology* 2001; **43**: 15–18.

40 Hong CJ, Lai IC, Liou LL, Tsai SJ: Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder. *Neurosci Lett* 2004; **355**: 69–72.

Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)